# PURPOSE 2 Trial: 96% Prevention in MSM/Trans

**ID:** TRT-003
**Year:** 2024
**Source:** Gilead
**Link:** [https://avac.org/lenacapavir/](https://avac.org/lenacapavir/)

---

## Abstract

Phase 3 trial demonstrating 96% reduction in HIV acquisition among MSM, transgender, and gender non-binary individuals.

---

## Key Concepts

- Primary research focus from 2023-2025 HIV literature
- Relevant to understanding HIV biology, treatment, or prevention
- Contributes to the broader HIV research landscape

---

## Relevance to Project

This paper contributes to the Ternary VAE bioinformatics project by providing context on:
- HIV sequence evolution and variability
- Biological constraints on viral fitness
- Therapeutic targets and resistance mechanisms

---

*Added: 2025-12-24*
